NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Organ & Specialty Systems/BPC-157 (Gut-Focused)

BPC-157 (Gut-Focused)

BPC-157 viewed through its gastrointestinal research profile: a gastric-juice-derived pentadecapeptide studied in animal models of ulcer and intestinal injury.

Overview

This entry covers the same synthetic pentadecapeptide as BPC-157, with emphasis on its gastrointestinal research profile, one of the most extensively studied areas for this peptide in animal models. The sequence is related to a protein constituent of human gastric juice, and the peptide is notable for its stability in that environment.

The Zagreb research group associated with Sikiric has reported protective and healing effects across numerous experimental models of gastrointestinal injury.

Mechanism

Proposed mechanisms in the gut include modulation of the nitric oxide system, maintenance of mucosal blood flow, anti-inflammatory effects, and support of tissue-repair mechanisms; the peptide has been reported to protect against lesions induced by a range of ulcerogenic agents.

As with other BPC-157 work, most mechanistic data come from rodent studies, and a definitive molecular target has not been established.

Dosing

No approved or validated dosing exists for human use. Published animal studies use systemic administration at microgram-per-kilogram doses, with regimens varying by model.

  • Systemic (typically intraperitoneal) administration in rodent models
  • Microgram-per-kilogram dosing reported across studies
  • Some protocols administer the peptide before injury (protective) and others after injury (therapeutic)

Expected Effects

  • Reduced severity of experimentally induced gastric and duodenal lesions in rodents
  • Protective effects reported against NSAID-type intestinal injury in animal models
  • Improved healing reported in models of intestinal anastomosis and colitis-like inflammation
  • Findings are preclinical; human gastrointestinal data are lacking

Side Effects & Tolerability

Reported tolerability in animal studies is generally good at the doses tested. No adequate human safety data exist, and effects after long-term use are unknown.

Storage

Store lyophilized peptide frozen (at or below -20 degrees C), desiccated, and protected from light. After reconstitution, refrigerate and use within the supplier's stated stability window, avoiding repeated freeze-thaw.

Related peptides

Adrenal Cortex Peptide FragmentsCatalog grouping of peptides marketed as adrenal-cortex-related tissue peptides; no standardized identity or peer-reviewed characterization is documented.Adrenomedullin AnalogsCatalog entry for marketed peptides labeled as adrenomedullin analogs; sequences are undisclosed and the products lack published characterization.ARA-290Synthetic 11-amino-acid peptide derived from the helix-B domain of erythropoietin, studied in clinical trials for neuropathic and small-fiber nerve injury.Cochlear Protection PeptidesCatalog name for peptides claimed to protect hearing; otoprotection is real research, but these products are undefined.Enamel & Dentin Repair AnalogsCatalog category implying peptides for enamel or dentin repair; matrix-derived peptides are real research, but these products are undocumented.GLP-2 AnalogsClass entry for analogs of the intestinotrophic hormone GLP-2, including the approved drug teduglutide for short bowel syndrome.